Mostrar el registro sencillo del documento

dc.creatorFreedberg, Daniel E.
dc.creatorConigliaro, Joseph
dc.creatorWang, Timothy C.
dc.creatorTracey, Kevin J.
dc.creatorCallahan, Michael V.
dc.creatorAbrams, Julian A.
dc.creatorSobieszczyk, Magdalena E.
dc.creatorMarkowit, David D.
dc.creatorGupta, Aakritiz
dc.creatorO’Donnell, Max R.
dc.creatorLi, Jianhua
dc.creatorTuveson, David A.
dc.creatorJin, Zhezhen
dc.creatorTurner, William C.
dc.creatorLandry, Donald W.
dc.date.accessioned2020-07-28T19:34:38Z
dc.date.available2020-07-28T19:34:38Z
dc.date.created2020
dc.identifier.otherhttps://doi.org/10.1053/j.gastro.2020.05.053spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11297
dc.description.abstractCOVID-19 caused 2 million cases and over 150,000 deaths worldwide as of mid-April 2020 (1). Clinical trials are underway to assess the efficacy of a variety of antiviral drugs. However, many of these drugs have toxicities and thus far no drug has been proven to improve outcomes in COVID-19 patients.spa
dc.format.extent17 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherGastroenterologyeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCoronavirus 2019spa
dc.subjectSARS-CoV-2spa
dc.subjectFamotidinespa
dc.subjectHistamine-2 receptor antagonistsspa
dc.titleFamotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort studyspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1053/j.gastro.2020.05.053spa


Archivos en el documento

Thumbnail
Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento